share_log

BRII-B Covid Combination Therapy Retains Neutralizing Activity against Omicron

BRII-B Covid Combination Therapy Retains Neutralizing Activity against Omicron

BRII-B联合治疗保留对奥密克戎的中和活性
阿斯达克财经 ·  2022/07/27 04:50

BRII-B (02137.HK) announced new live virus data confirming that the amubarvimab/ romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains
neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.
The U.S. Food and Drug Administration is currently reviewing the Company's Emergency Use Authorization application for the amubarvimab/ romlusevimab combination.

BRII-B(02137.HK)公布了新的活病毒数据,证实了长效新冠肺炎单抗疗法阿米巴韦/罗鲁塞米联合治疗保留了
对奥密克戎BA.4/5和BA.2.12.1 SARS-CoV-2亚型的中和活性。
美国食品和药物管理局目前正在审查该公司对amubarvimab/romlusevimab组合的紧急使用授权申请。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发